ArticleBMC ophthalmology2025
The effect of guanfacine treatment on ocular parameters in pediatric and adolescents patients with attention-deficit/hyperactivity disorder.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optical coherence tomography angiography findings in ADHD.BMC ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the effects of guanfacine on the anterior and posterior segments of the eye.
methodsThis prospective study included 32 children and adolescents with Attention-deficit/hyperactivity disorder (ADHD). The participants underwent a detailed ophthalmologic evaluation before and 6 months after the beginning of guanfacine treatment. The following data were recorded for each participant: refraction error, intraocular pressure (IOP), anterior chamber depth (ACD), central corneal thickness (CCT), corneal aberrations using corneal topography, retinal nerve fiber layer (RNFL) analysis of seven quadrants (central, nasal, naso-superior, naso-inferior, temporal, temporo-superior, temporo-inferior), central macular thickness (CMT), and choroidal thickness (CT). Assessments were made of these parameters obtained from images using an optical coherence tomography (OCT) instrument.
resultsA significant increase in total root mean square (RMS) (p = 0.029*), RMS low-order aberration (LOA) (p = 0.014*), Coma 0° (p < 0.001*), and Coma 90° (p = 0.037*) corneal aberrations was observed at the sixth month of guanfacine treatment in comparison with the baseline examination. Other ocular parameters demonstrated no significant change from the baseline examination findings at the sixth month of guanfacine treatment. (p > 0.05, for each).
conclusionOral guanfacine in the treatment of ADHD had no effect on ocular structures such as the retina, choroid, optic nerve, refraction, or corneal thickness, although it increased corneal aberrations. The results require support through further studies with extended follow-up and a larger patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.